Latest Biotech News

GSK has outlined a late-stage development plan for a gynecological cancer antibody-drug conjugate (ADC) licensed from Hansoh Pharma after early promising data. The UK drugmaker said it intends to...

Researchers reported a dual-CAR strategy aimed at improving allogeneic CD19 CAR T cell performance by addressing two major failure modes: antigen escape and alloimmune rejection. The approach...

A new high-throughput approach targets MDM2 as a way to overcome radiation resistance in uveal melanoma. The work is designed to identify and validate combinations or mechanisms that can sensitize...

Sidewinder Therapeutics and Stipple Bio each secured large financing rounds to advance approaches for improving the targeting abilities of antibody drug conjugates (ADCs) for cancer. Both...

A new report flags that the biopharma R&D pipeline has shrunk for the first time in 30 years, raising questions about how quickly new programs are entering development across the sector. The story...

The CDC delayed the planned release of an observational study intended to show COVID vaccines reduced severe illness risk, according to reporting in the article. The piece says Acting CDC director...

Researchers developed tumor-targeted nanoparticles designed to co-deliver a macrophage engager mRNA alongside PD-L1 antibodies to boost glioblastoma immunotherapy efficacy. The work, published in...

Agilent highlighted how lab automation and instrumentation are being used to scale antibody-drug conjugate (ADC) characterization workflows. The story focuses on practical acceleration and...

Relacorilant (Lifyorli) added to nab-paclitaxel (Abraxane) produced a statistically significant overall survival improvement in the phase 3 ROSELLA trial for platinum-resistant ovarian cancer,...

Replimune Group received a second complete response letter (CRL) from the U.S. FDA for its immunotherapy vusolimogene oderparepvec in advanced melanoma, with the decision tied to an April 10 PDUFA...

Oricell Therapeutics secured $110 million to expand its cell therapy platform aimed at GPC3-positive liver cancers, where there are currently no FDA-approved therapies. The company positions its...

Researchers reported a new allogeneic CAR T-cell design that uses an anti-rejection CD70 CAR to help manage alloimmune rejection while also targeting CD19, aiming to reduce both antigen escape and...

Novartis flagged a first annual profit drop in years for 2026 as key patents expire on blockbuster therapies including Entresto and Xolair, warning that generic competition could drive roughly $4...

A study presented a CAR T-cell optimization approach that modulates receptor affinity to balance anti-tumor efficacy with safety risk. The work focuses on receptor-ligand binding characteristics...

A report raises urgent governance concerns around AI systems that can design and run thousands of biological experiments with minimal human involvement, arguing that oversight mechanisms are...

FairJourney Bio opened a cryo-electron microscopy (cryo-EM) structural biology facility in San Diego to embed atomic-resolution structure determination into its antibody discovery platform. The...

The University of Cincinnati started a clinical trial for investigational treatments targeting prosthetic joint infections (PJI), with initial patient enrollments reported. The study is led by...

A cross-institution team led by Mass General Brigham, Dana-Farber Cancer Institute, and the Broad Institute identified a novel immune evasion mechanism in acute myeloid leukemia involving the...

Relacorilant (Lifyorli) plus nab-paclitaxel has posted final overall survival results in ROSELLA, a phase 3 study in platinum-resistant ovarian cancer, delivering a statistically significant...

FDA has again refused to move forward with Replimune’s oncolytic virus therapy for advanced melanoma, according to reports tied to another complete response letter. The agency said the company...